Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMP NASDAQ:MNOV NASDAQ:NCEL NASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPPrima BioMed$0.52+15.1%$0.72$0.29▼$3.53$66.52M2.242.67 million shs2.38 million shsMNOVMediciNova$1.38-1.4%$1.41$1.17▼$1.96$67.93M0.6320,139 shs17,835 shsNCELNLS Pharmaceutics$3.21-6.4%$2.86$1.83▼$30.80$18.33M1.0180,725 shs13,287 shsTCRXTScan Therapeutics$1.00-9.9%$1.12$0.88▼$2.57$72.54M1.06969,503 shs840,890 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPPrima BioMed+15.13%+16.52%-4.47%-80.31%-71.60%MNOVMediciNova-1.43%-1.43%-3.50%-6.76%+0.73%NCELNLS Pharmaceutics-6.41%-4.46%+28.40%+15.88%-80.55%TCRXTScan Therapeutics-9.91%-20.63%-6.54%+7.30%-21.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPPrima BioMed$0.52+15.1%$0.72$0.29▼$3.53$66.52M2.242.67 million shs2.38 million shsMNOVMediciNova$1.38-1.4%$1.41$1.17▼$1.96$67.93M0.6320,139 shs17,835 shsNCELNLS Pharmaceutics$3.21-6.4%$2.86$1.83▼$30.80$18.33M1.0180,725 shs13,287 shsTCRXTScan Therapeutics$1.00-9.9%$1.12$0.88▼$2.57$72.54M1.06969,503 shs840,890 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPPrima BioMed+15.13%+16.52%-4.47%-80.31%-71.60%MNOVMediciNova-1.43%-1.43%-3.50%-6.76%+0.73%NCELNLS Pharmaceutics-6.41%-4.46%+28.40%+15.88%-80.55%TCRXTScan Therapeutics-9.91%-20.63%-6.54%+7.30%-21.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMPPrima BioMed 1.75Reduce$5.50958.30% UpsideMNOVMediciNova 2.86Moderate Buy$7.50443.48% UpsideNCELNLS Pharmaceutics 1.00SellN/AN/ATCRXTScan Therapeutics 2.33Hold$6.00500.00% UpsideCurrent Analyst Ratings BreakdownLatest NCEL, IMMP, MNOV, and TCRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026MNOVMediciNova D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.004/21/2026TCRXTScan Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026MNOVMediciNova Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/23/2026MNOVMediciNova Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.003/17/2026MNOVMediciNova Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/16/2026MNOVMediciNova HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.003/13/2026IMMPPrima BioMed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold3/13/2026IMMPPrima BioMed Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$7.00 ➝ $1.003/13/2026IMMPPrima BioMed Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/5/2026TCRXTScan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $5.002/23/2026IMMPPrima BioMed Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$10.00(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMPPrima BioMed$6.69M11.45N/AN/A$0.63 per share0.82MNOVMediciNova$409.66K165.81N/AN/A$0.85 per share1.62NCELNLS PharmaceuticsN/AN/AN/AN/A$1.59 per shareN/ATCRXTScan Therapeutics$9.14M7.15N/AN/A$1.48 per share0.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMPPrima BioMed-$39.78MN/AN/AN/AN/AN/AN/AN/AN/AMNOVMediciNova-$12M-$0.23N/AN/AN/A-1,962.98%-26.55%-24.58%N/ANCELNLS Pharmaceutics-$8.30MN/AN/AN/AN/AN/AN/AN/AN/ATCRXTScan Therapeutics-$129.77M-$0.96N/AN/AN/A-1,360.61%-91.94%-50.15%N/ALatest NCEL, IMMP, MNOV, and TCRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026MNOVMediciNova-$0.06-$0.05+$0.01-$0.05$186.98 million$0.19 million5/6/2026Q1 2026TCRXTScan Therapeutics-$0.22-$0.22N/A-$0.22$2.50 million$0.98 million3/4/2026Q4 2025TCRXTScan Therapeutics-$0.27-$0.18+$0.09-$0.18$2.44 million$2.57 million2/20/2026Q4 2025MNOVMediciNova-$0.0950-$0.05+$0.0450-$0.05N/A$0.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMMPPrima BioMedN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ANCELNLS PharmaceuticsN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMPPrima BioMedN/A2.97N/AMNOVMediciNovaN/A8.168.16NCELNLS PharmaceuticsN/A0.760.76TCRXTScan Therapeutics0.346.656.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMPPrima BioMed2.32%MNOVMediciNova9.90%NCELNLS PharmaceuticsN/ATCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipIMMPPrima BioMed3.07%MNOVMediciNova14.00%NCELNLS Pharmaceutics16.40%TCRXTScan Therapeutics6.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMPPrima BioMed2,021147.37 million142.85 millionOptionableMNOVMediciNova1049.22 million42.33 millionOptionableNCELNLS Pharmaceutics65.35 million4.47 millionNot OptionableTCRXTScan Therapeutics10065.35 million61.27 millionNot OptionableNCEL, IMMP, MNOV, and TCRX HeadlinesRecent News About These CompaniesTScan Therapeutics (NASDAQ:TCRX) Cut to "Strong Sell" at Wall Street ZenMay 9, 2026 | marketbeat.comQ2 EPS Estimates for TScan Therapeutics Cut by HC WainwrightMay 8, 2026 | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Hits ExpectationsMay 6, 2026 | marketbeat.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Hold" by AnalystsMay 5, 2026 | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from BrokeragesMay 5, 2026 | marketbeat.comTScan Therapeutics (TCRX) Expected to Announce Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual MeetingApril 27, 2026 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 7.40%April 18, 2026 | aaii.comATScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | globenewswire.comTScan Therapeutics Consolidates Finance Leadership After Officer ResignationApril 2, 2026 | tipranks.comStrong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy SpaceMarch 25, 2026 | insidermonkey.comTScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue EstimatesMarch 4, 2026 | zacks.comTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 4, 2026 | globenewswire.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102 ...February 26, 2026 | markets.businessinsider.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03February 26, 2026 | globenewswire.comTScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceFebruary 25, 2026 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 7.51%December 25, 2025 | aaii.comATScan Therapeutics (NASDAQ:TCRX) Major Shareholder Acquires $67,950.00 in StockDecember 24, 2025 | insidertrades.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Down 13.80%December 9, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeNCEL, IMMP, MNOV, and TCRX Company DescriptionsPrima BioMed NASDAQ:IMMP$0.52 +0.07 (+15.13%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.52 0.00 (-0.52%) As of 05/15/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.MediciNova NASDAQ:MNOV$1.38 -0.02 (-1.43%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.38 0.00 (0.00%) As of 05/15/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.NLS Pharmaceutics NASDAQ:NCEL$3.21 -0.22 (-6.41%) As of 05/15/2026 04:00 PM EasternNLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.TScan Therapeutics NASDAQ:TCRX$1.00 -0.11 (-9.91%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.01 +0.01 (+1.50%) As of 05/15/2026 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
